3.45 -0.03 (-0.86%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 4.67 | 1-year : | 5.46 |
Resists | First : | 4 | Second : | 4.67 |
Pivot price | 3.39 ![]() |
|||
Supports | First : | 2.9 | Second : | 2.41 |
MAs | MA(5) : | 3.46 ![]() |
MA(20) : | 3.5 ![]() |
MA(100) : | 3.45 ![]() |
MA(250) : | 3.14 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 53.6 ![]() |
D(3) : | 52.3 ![]() |
RSI | RSI(14): 47.5 ![]() |
|||
52-week | High : | 4.96 | Low : | 2.13 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GRCE ] has closed below upper band by 41.5%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.47 - 3.49 | 3.49 - 3.51 |
Low: | 3.33 - 3.35 | 3.35 - 3.37 |
Close: | 3.42 - 3.45 | 3.45 - 3.48 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Thu, 13 Feb 2025
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - The Manila Times
Thu, 13 Feb 2025
Grace Therapeutics Inc. (GRCE) reports earnings - Quartz
Thu, 13 Feb 2025
Grace Reports Clinical Trial Victory and Major Cash Infusion in Latest Earnings - StockTitan
Wed, 12 Feb 2025
Grace Therapeutics secures up to $30 million financing - MSN
Mon, 10 Feb 2025
Grace Therapeutics Shares Rise After Private Placement Financing of up to $30 Million - Marketscreener.com
Mon, 10 Feb 2025
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 10 (M) |
Shares Float | 5 (M) |
Held by Insiders | 38.3 (%) |
Held by Institutions | 21.3 (%) |
Shares Short | 128 (K) |
Shares Short P.Month | 129 (K) |
EPS | -1.29 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.57 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -11.7 % |
Return on Equity (ttm) | -18.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.31 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -10 (M) |
Levered Free Cash Flow | -6 (M) |
PE Ratio | -2.68 |
PEG Ratio | 0 |
Price to Book value | 0.52 |
Price to Sales | 0 |
Price to Cash Flow | -3.62 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |